Table 3.

Summary of efficacy outcomes in the safety population

Efficacy outcome	LEB 250 mg Q2W
EASI-75
Week 4	59 (28.6) [22.4, 34.8]
Week 16	151 (73.2) [67.0, 79.4]
Week 52	169 (81.9) [76.5, 87.4]
EASI-90
Week 4	25 (12.0) [7.5, 16.5]
Week 16	91 (44.0) [37.1, 50.9]
Week 52	127 (61.4) [54.5, 68.3]
EASI-50
Week 4	118 (57.2) [50.4, 64.0]
Week 16	186 (90.3) [86.2, 94.5]
Week 52	194 (94.4) [91.1, 97.7]
EASI % change from baseline, mean (SE)
Week 4	− 54.1 (2.1)
Week 16	− 81.0 (1.6)
Week 52	− 86.0 (1.6)
IGA (0,1) with ≥ 2-point reduction from baseline
Week 4	30 (14.4) [9.5, 19.2]
Week 16	95 (46.3) [39.3, 53.2]
Week 52	129 (62.6) [55.6, 69.6]
BSA change from baseline, mean (SD)
Week 4	− 19.9 (16.9)
Week 16	− 33.5 (19.4)
Week 52	− 37.6 (21.1)
DLQI change from baseline, mean (SE)
Week 16	− 6.9 (0.9)
Week 32	− 8.6 (0.9)
Week 52	− 8.9 (0.9)
CDLQI change from baseline, mean (SE)
Week 16	− 6.1 (0.4)
Week 32	− 6.2 (0.4)
Week 52	− 6.5 (0.5)
PROMIS anxiety score change from baseline, mean (SD)
Week 16	− 6.2 (9.4)
Week 32	− 6.8 (10.3)
Week 52	− 6.3 (10.0)
PROMIS depression score change from baseline, mean (SD)
Week 16	− 3.1 (8.5)
Week 32	− 3.3 (8.7)
Week 52	− 3.4 (9.1)

Data are presented as N (%) [95% CI] unless specified in the table

Abbreviations: BSA Body Surface Area, CDLQI Children’s Dermatology Life Quality Index, DLQI Dermatology Life Quality Index, EASI Eczema Area and Severity Index, EASI-50 50% reduction in EASI, EASI-75 75% reduction in EASI, EASI-90 90% reduction in EASI, IGA Investigator’s Global Assessment, LEB lebrikizumab, n number of patients in the specified category, PROMIS Patient-Reported Outcomes Measurement Information System, Q2W every 2 weeks, SD standard deviation, SE standard error